LENZ Valuation

LENZ Therapeutics Inc

Add to Watchlist

Advanced Chart

30.170

-0.31(-1.017%)1D

Overview
Forecast
Valuation
Earnings

LENZ Relative Valuation

LENZ's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LENZ is overvalued; if below, it's undervalued.

Historical Valuation

LENZ Therapeutics Inc (LENZ) is now in the Undervalued zone, suggesting that its current forward PS ratio of 43.08 is considered Undervalued compared with the five-year average of -10.32. The fair price of LENZ Therapeutics Inc (LENZ) is between 168.34 to 225.16 according to relative valuation methord. Compared to the current price of 29.30 USD , LENZ Therapeutics Inc is Undervalued By 82.59%.

Relative Value

Fair Zone

168.34-225.16

Current Price：29.30

82.59%

Undervalued

-9.85

Trailing

Forward

-8.49

EV/EBITDA

LENZ Therapeutics Inc. (LENZ) has a current EV/EBITDA of -8.49. The 5-year average EV/EBITDA is -7.89. The thresholds are as follows: Strongly Undervalued below -13.43, Undervalued between -13.43 and -10.66, Fairly Valued between -5.12 and -10.66, Overvalued between -5.12 and -2.35, and Strongly Overvalued above -2.35. The current Forward EV/EBITDA of -8.49 falls within the Historic Trend Line -Fairly Valued range.

-6.51

EV/EBIT

LENZ Therapeutics Inc. (LENZ) has a current EV/EBIT of -6.51. The 5-year average EV/EBIT is -6.78. The thresholds are as follows: Strongly Undervalued below -10.84, Undervalued between -10.84 and -8.81, Fairly Valued between -4.75 and -8.81, Overvalued between -4.75 and -2.72, and Strongly Overvalued above -2.72. The current Forward EV/EBIT of -6.51 falls within the Historic Trend Line -Fairly Valued range.

42.17

LENZ Therapeutics Inc. (LENZ) has a current PS of 42.17. The 5-year average PS is 53.41. The thresholds are as follows: Strongly Undervalued below -50.87, Undervalued between -50.87 and 1.27, Fairly Valued between 105.55 and 1.27, Overvalued between 105.55 and 157.69, and Strongly Overvalued above 157.69. The current Forward PS of 42.17 falls within the Historic Trend Line -Fairly Valued range.

-12.45

P/OCF

LENZ Therapeutics Inc. (LENZ) has a current P/OCF of -12.45. The 5-year average P/OCF is -10.04. The thresholds are as follows: Strongly Undervalued below -14.88, Undervalued between -14.88 and -12.46, Fairly Valued between -7.62 and -12.46, Overvalued between -7.62 and -5.20, and Strongly Overvalued above -5.20. The current Forward P/OCF of -12.45 falls within the Historic Trend Line -Fairly Valued range.

-8.34

P/FCF

LENZ Therapeutics Inc. (LENZ) has a current P/FCF of -8.34. The 5-year average P/FCF is -8.90. The thresholds are as follows: Strongly Undervalued below -13.75, Undervalued between -13.75 and -11.33, Fairly Valued between -6.47 and -11.33, Overvalued between -6.47 and -4.05, and Strongly Overvalued above -4.05. The current Forward P/FCF of -8.34 falls within the Historic Trend Line -Fairly Valued range.

LENZ Therapeutics Inc (LENZ) has a current Price-to-Book (P/B) ratio of 4.05. Compared to its 3-year average P/B ratio of 3.22 , the current P/B ratio is approximately 25.78% higher. Relative to its 5-year average P/B ratio of 3.22, the current P/B ratio is about 25.78% higher. LENZ Therapeutics Inc (LENZ) has a Forward Free Cash Flow (FCF) yield of approximately -5.61%. Compared to its 3-year average FCF yield of -10.71%, the current FCF yield is approximately -47.64% lower. Relative to its 5-year average FCF yield of -10.71% , the current FCF yield is about -47.64% lower.

4.21

P/B

Median3y

3.22

Median5y

3.22

-5.73

FCF Yield

Median3y

-10.71

Median5y

-10.71

Competitors Valuation Multiple

The average P/S ratio for LENZ's competitors is 1094.50, providing a benchmark for relative valuation. LENZ Therapeutics Inc Corp (LENZ) exhibits a P/S ratio of 42.17, which is -96.15% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

LENZ.O

LENZ Therapeutics Inc

Oric Pharmaceuticals Inc

Loss

842.02M

ATAI.O

ATAI Life Sciences NV

Performance Decomposition

Market capitalization of LENZ increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of LENZ in the past 1 year is driven by Unknown.